

Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, Sugiyama M, Murata K, Fukuhara T, Matsuura Y, Hayashi N, <u>Mizokami M</u> , Takehara T.	Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon- λ in response to hepatitis C virus.	Hepatology	57 (5)	1705-15	2013
Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsushashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, <u>Mizokami M</u> .	Hepatitis C virus kinetics by administration of pegylated interferon- α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.	Gut	62 (9)	1340-6	2013
Nao Nishida, <u>Katsushi Tokunaga</u> , Masashi Mizokami	Genome-Wide Association Study Reveals Host Genetic Factors for Liver Diseases	Journal of Clinical and Translational Hepatology	1	45-50	2013
西田奈央、 <u>徳永勝士</u> 、溝上雅史	高密度マイクロアレイによるゲノムワイド関連解析 (GWAS) の実際	肝胆膵	67(1)	7-14	2013

IV. 研究成果の刊行物、別刷

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

Yuji Urabe^{1,2}, Hidenori Ochi², Naoya Kato⁴, Vinod Kumar^{1,3}, Atsushi Takahashi³, Ryosuke Muroyama⁴, Naoya Hosono³, Motoyuki Otsuka⁵, Ryosuke Tateishi⁵, Paulisally Hau Yi Lo¹, Chizu Tanikawa¹, Masao Omata⁵, Kazuhiko Koike⁵, Daiki Miki², Hiromi Abe², Naoyuki Kamatani³, Joji Toyota⁶, Hiromitsu Kumada⁷, Michiaki Kubo³, Kazuaki Chayama², Yusuke Nakamura^{1,3}, Koichi Matsuda^{1,*}

¹Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ²Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; ³Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan; ⁴Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ⁵Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ⁶Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan; ⁷Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Background & Aims: We performed a genome-wide association study (GWAS) of hepatitis C virus (HCV)-induced liver cirrhosis (LC) to identify predictive biomarkers for the risk of LC in patients with chronic hepatitis C (CHC).

Methods: A total of 682 HCV-induced LC cases and 1045 CHC patients of Japanese origin were genotyped by Illumina Human Hap 610-Quad bead Chip.

Results: Eight SNPs which showed possible associations ($p < 1.0 \times 10^{-5}$) at the GWAS stage were further genotyped using 936 LC cases and 3809 CHC patients. We found that two SNPs within the major histocompatibility complex (MHC) region on chromosome 6p21, rs910049 and rs3135363, were significantly associated with the progression from CHC to LC ($p_{\text{combined}} = 9.15 \times 10^{-11}$ and 1.45×10^{-10} , odds ratio (OR) = 1.46 and 1.37, respectively). We also found that *HLA-DQA1*0601* and *HLA-DRB1*0405* were associated with the progression from CHC to LC ($p = 4.53 \times 10^{-4}$ and 1.54×10^{-4} with OR = 2.80 and 1.45, respectively). Multiple logistic regression analysis revealed that rs3135363, rs910049, and *HLA-DQA1*0601* were independently associated with the risk of HCV-induced LC. In addition, individ-

uals with four or more risk alleles for these three loci have a 2.83-fold higher risk for LC than those with no risk allele, indicating the cumulative effects of these variations.

Conclusions: Our findings elucidated the crucial roles of multiple genetic variations within the MHC region as prognostic/predictive biomarkers for CHC patients.

© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Two million people in Japan and 210 million people worldwide are estimated to be infected with the hepatitis C virus (HCV), which is known to be a major cause of chronic viral liver disease [1]. Patients with chronic hepatitis C (CHC) usually exhibit mild inflammatory symptoms, but are at a significantly high risk for developing liver cirrhosis (LC) and hepatocellular carcinoma [2]. More than 400,000 people at present suffer from LC, which is ranked as the 9th major cause of death in Japan. In addition, liver cancer causes approximately 32,000 deaths per year, making it the 4th most common cause of death from malignant diseases. Thus, HCV-related diseases are important public health problems [3].

Clinical outcomes after the exposure to HCV vary enormously among individuals. Approximately 70% of infected persons will develop chronic hepatitis [4], and about 20–30% of CHC patients will develop cirrhosis, but others can remain asymptomatic for decades [2]. The annual death rate of patients with decompensated cirrhosis is as high as 15–30% [5]. Moreover, more than 7% of LC patients develop hepatocellular cancer in Japan and Taiwan, while the frequencies are less than 1.6% among other ethnic groups [6,7]. These inter-individual and inter-ethnic differences have been attributed to various factors such as viral genotypes,

Keywords: Genome-wide association study; Hepatitis C virus; Liver cirrhosis; Major histocompatibility complex.

Received 22 April 2012; received in revised form 15 December 2012; accepted 24 December 2012; available online 12 January 2013

* Corresponding author. Address: Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato, Tokyo 108-8639, Japan. Tel.: +81 3 5449 5376; fax: +81 3 5449 5123.

E-mail address: koichima@ims.u-tokyo.ac.jp (K. Matsuda).

Abbreviations: CHC, chronic hepatitis C; GWAS, genome-wide association study; HCV, hepatitis C virus; LC, liver cirrhosis; MHC, major histocompatibility complex; OR, odds ratio; PBC, primary biliary cirrhosis; SNPs, single nucleotide polymorphisms.



Research Article

Table 1. Characteristics of samples and methods used in this study.

Stage	Source	Platform	Number of samples	Female (%)	Age, yr (mean $\pm$ SD)
GWAS					
Liver cirrhosis	BioBank Japan	Illumina Human Hap 610	682	313 (46.3)	67.1 $\pm$ 9.7
Chronic hepatitis C ^a	Hiroshima University	Illumina Human Hap 610	1045	371 (35.5)	55.2 $\pm$ 11.0
Replication					
Liver cirrhosis	Tokyo University	Invader assay	716	334 (46.8)	64.4 $\pm$ 10.4
	Hiroshima University		220	98 (44.5)	64.7 $\pm$ 8.98
Chronic hepatitis C ^a	BioBank Japan	Invader assay	1670	780 (46.8)	59.7 $\pm$ 12.6
	Hiroshima University		2139	1061 (51.8)	58.8 $\pm$ 9.20

^aNumber of samples that qualified. CHC patients with severe liver fibrosis (F3 or F4) or lower platelet counts (<160,000) were excluded.

alcohol consumption, age at infection, co-infection of HIV or HBV [8–10], insulin resistance, steatosis, and metabolic syndrome [11]. Previous gene expression analyses also identified various genes associated with liver fibrosis among patients with CHC [12–14]. In addition, miRNAs such as mir-21 and mir-122 were shown to be correlated with liver fibrosis [15,16].

Currently, the genome-wide association study is the most common method to identify genetic variations associated with disease risk [17–20]. In addition, the roles of genetic factors in HCV-related diseases have been elucidated. *IL28B* is associated with spontaneous clearance of HCV [21] as well as with the clinical response to the combination therapy of pegylated interferon and ribavirin [22,23]. Recently, our group has shown that SNP rs2596542 on *MICA* [24] and SNP rs1012068 on *DEPDC5* [25] are significantly associated with HCV-induced liver cancer. Although liver cirrhosis is the major risk factor of liver cancer, a fraction of CHC patients will develop HCC without accompanying LC. Therefore, the underlying genetic background would be different between HCV-induced LC and HCV-induced HCC. Previous studies identified the association of genetic variants in *HLA-DQ/DR/B* [26–28], *2–5AS* [29], *TLR3* [30], and *PNPLA3* [31] with the risk of liver fibrosis among patients with CHC. However, a comprehensive approach for HCV-induced LC has not been conducted so far. Here we performed GWAS of HCV-induced LC to identify predictive biomarkers for the risk of LC in patients with CHC.

Materials and methods

Ethics statement

All subjects provided written informed consent. This project was approved by the ethical committees at University of Tokyo, Hiroshima University, Sapporo Kosei General Hospital, Toranomon Hospital, and Center for Genomic Medicine, Institutes of Physical and Chemical Research (RIKEN).

Study population

The characteristics of each cohort are shown in Table 1. In this study, we conducted GWAS and replication analysis on a total of 1618 HCV-induced LC and 4854 CHC patients. All subjects had abnormal levels of serum alanine transaminase for more than 6 months and were positive for both HCV antibody and serum HCV RNA. Among 1618 LC and 4854 CHC samples, 342 LC patients (21.14%) and 2997 CHC patients (61.70%) underwent liver biopsy. The remaining 1276 LC and 1857 CHC patients were diagnosed by non-invasive methods including hepatic imaging (e.g., ultrasonography, computed tomography, arteriography or magnetic resonance imaging), biochemical data (serum bilirubin, serum albumin, platelet, or prothrombin time), and the presence/absence of clinical manifestations of portal hypertension (e.g., varices, encephalopathy or ascites). The patients with CHC

or LC were recruited for this study regardless of their treatment history. We excluded from the analysis the followings CHC patients: (1) advanced liver fibrosis (F3 or F4 by New Inuyama classification) [32], (2) platelet count under 160,000 for patients without liver fibrosis staging, and (3) HBV co-infection. Characteristics of each study cohort are shown in Table 1. In brief, DNA of HCV-induced LC and CHC patients was obtained from Biobank Japan (<http://biobankjp.org/>) [33], the Hiroshima Liver Study Group (<http://home.hiroshima-u.ac.jp/naika1/researchprofile/pdf/liverstudygroupe.pdf>), Toranomon Hospital, and the University of Tokyo. All subjects were of Japanese origin.

SNP genotyping

Genomic DNA was extracted from peripheral blood leukocytes using a standard method. In GWAS, we genotyped 682 LC and 1045 CHC samples using Illumina Human Hap 610-Quad bead Chip (Supplementary Fig. 1). Samples with low call rate (<0.98) were excluded from our analysis (six LC and two CHC samples). We then applied SNP quality control as follows: call rate ≥ 0.99 in LC and CHC samples, Hardy-Weinberg $p \geq 1 \times 10^{-6}$ in LC and CHC samples. Consequently, 461,992 SNPs on the autosomal chromosomes passed the quality control filters. SNPs with minor allele frequency of <0.01 in both LC and CHC samples were excluded from further analyses, considering statistical power in the replication analysis. Finally, we analyzed 431,618 SNPs in GWAS. Among the top ten SNPs showing $p < 1.0 \times 10^{-5}$, we selected nine SNPs for further analysis with LD threshold of $r^2 = 0.95$. In the replication stage, we genotyped 936 LC and 3809 CHC using multiplex PCR-based Invader assay (Third Wave Technologies).

Statistical analysis

The association of SNPs with the phenotype in the GWAS, replication stage, and combined analyses was tested by logistic regression analysis, upon adjusting for age at recruitment (continuous) and gender, by assuming additive model using PLINK [34]. In the GWAS, the genetic inflation factor λ was derived by applying logistic regressed p values for all the tested SNPs. The quantile-quantile plot was drawn using R program. The odds ratios were calculated using the non-susceptible allele as reference, unless stated otherwise. The combined analysis of GWAS and replication stage was verified by using the Mantel-Haenszel method. We set the significance threshold as follows; $p = 1 \times 10^{-5}$ in the GWAS stage (first stage) and $p = 6.25 \times 10^{-3}$ ($=0.05/8$) in the replication analysis. We considered $p < 5 \times 10^{-8}$ as threshold of GWAS significance in the combined analysis, which is the Bonferroni-corrected threshold for the number of independent SNPs genotyped in HapMap Phase II [35]. The heterogeneity across two stages was examined by using the Breslow-Day test [36]. We used Haploview software to analyze the association of haplotypes and LD values between SNPs. Quality control for SNPs was applied as follows: call rate ≥ 0.95 in LC and CHC samples, and Hardy-Weinberg $p \geq 1 \times 10^{-6}$ in CHC samples in replication stage. The statistical power was 19.51% in GWAS (the first stage) ($p = 1.00 \times 10^{-5}$), 97.98% in replication ($p = 0.05/8$), and 74.76% in the combined stage ($p = 5.00 \times 10^{-8}$) at minor allele frequency of 0.3 and OR of 1.3.

Imputation-based association analysis of HLA class I and class II alleles

We obtained an SNP or a combination of SNPs which could tag the HLA alleles in the Japanese population from a previous study [37]. Genotypes of tagging SNPs were imputed in the GWAS samples by using a Hidden Markov model programmed in MACH [38] and haplotype information from HapMap JPT samples




Fig. 1. Regional association plot at 6p21.3. (Upper panel) p Values of genotyped SNPs (circle) and imputed SNPs (cross) are plotted (as $-\log_{10} p$ value) against their physical position on chromosome 6 (NCBI Build 36). The p value for rs910049 at GWAS is represented by a purple diamond. Estimated recombination rates from HapMap JPT show the local LD structure. Inset; the color of the other SNPs indicates LD with rs3135363 according to a scale from $r^2 = 0$ to $r^2 = 1$ based on pair-wise r^2 values from HapMap JPT. (Lower panel) Gene annotations from the University of California Santa Cruz genome browser.

and 1000 genome imputation samples [39]. We applied the same SNP quality criteria as in GWAS, to select SNPs for the analysis. We employed the logistic regression analysis upon age and gender adjustment to assess the associations between HCV-induced LC and HLA alleles.

Software

For general statistical analysis, we employed R statistical environment version 2.9.1 (cran.r-project.org) or plink-1.06 (pngu.mgh.harvard.edu/~purcell/plink/). The Haploview software version 4.2 [40] was used to calculate LD and to draw Manhattan plot. Primer3 -web v0.3.0 (<http://frodo.wi.mit.edu>) web tool was used to design primers. We employed LocusZoom (<http://csg.sph.umich.edu/locuszoom/>) for regional plots. We used SNP Functional Prediction web tool for functional annotation of SNPs (<http://snpinfo.niehs.nih.gov/snpfunc.htm>) [41]. We used "Gene Expression Analysis Based on Imputed Genotypes" (<http://www.sph.umich.edu/csg/liang/imputation>) [42] for eQTL analysis. We used MACTH [43] web tool for searching potential binding sites for transcription factors (<http://www.gene-regulation.com/index.htm>).

Results

Genome-wide association study for HCV-induced liver cirrhosis

We performed a two-stage GWAS using a total of 1618 cases and 4854 controls (Supplementary Fig. 1). In the first stage, a whole genome scan was performed on 682 Japanese patients with HCV-induced LC and 1045 Japanese patients with CHC, using Illumina Human Hap 610-Quad bead Chip. The genotyping results of 431,618 single nucleotide polymorphisms (SNPs) obtained after our standard quality control were used for further analysis.

CHC patients with severe liver fibrosis (F3 or F4 according to the New Inuyama classification [32]) or lower platelet counts ($<160,000$) were excluded from the control group. As progression from CHC to LC is strongly affected by age and gender, we performed logistic regression analyses including age and gender as covariates at all tested loci in our analyses. The genetic inflation factor lambda was 1.051, indicating that there is little or no evidence of population stratification (Supplementary Fig. 2A). Although no SNPs cleared the GWAS significance threshold ($p < 5 \times 10^{-8}$) at the first stage, we selected ten candidate SNPs showing suggestive association of $p < 1 \times 10^{-5}$ (Supplementary Fig. 2B and Supplementary Table 1). After excluding SNP rs6891116 due to almost absolute linkage with SNP rs10252674 ($r^2 = 0.99$), the remaining nine SNPs were further genotyped using an independent cohort, consisting of 936 LC and 3809 CHC cases, by multiplex PCR-based Invader assay as the second stage. We could successfully obtain genotype results for eight SNPs after the QC filter (call rate ≥ 0.95 in LC and CHC samples, Hardy-Weinberg of $p \geq 1 \times 10^{-6}$ in CHC samples). The logistic regression analysis adjusted by age and gender revealed that five SNPs on chromosome 6q21.3 indicated a significant association with progression from CHC to LC after the Bonferroni correction ($p < 0.05/8 = 6.25 \times 10^{-3}$, Supplementary Table 2). A meta-analysis of the two stages with a fixed-effects model revealed that all of the five SNPs significantly associated with progression from CHC to LC (p values of 9.15×10^{-11} – 1.28×10^{-8} with odds ratios (OR) of 1.30–1.46, Fig. 1 and Table 2). These five SNPs were located in the HLA class II region and were in strong linkage disequilibrium with each other (D' > 0.75 ,

Research Article

Table 2. Summary of GWAS and replication analyses.

SNP	Stage	Allele (1/2)	Gene	Liver cirrhosis				Chronic hepatitis C				OR (95% CI) ^b	<i>p</i> value ^c	<i>p</i> value _{het} ^d	
				11	12	22	RAF ^a	11	12	22	RAF ^a				
rs910049															
	GWAS	a/g	<i>C6orf10</i> (6p21.3)	24	217	435	0.196	25	224	794	0.131	1.73 (1.40-2.15)	5.39 x 10 ⁻⁷		
	Replication			38	259	631	0.180	66	952	2790	0.142	1.37 (1.20-1.58)	7.59 x 10 ⁻⁶		
	Combined ^e											1.46 (1.28-1.62)	9.15 x 10 ⁻¹¹	0.075	
rs3817963															
	GWAS	a/g	<i>BTNL2</i> (6p21.3)	92	343	241	0.390	101	437	505	0.306	1.53 (1.29-1.81)	9.50 x 10 ⁻⁷		
	Replication			130	395	395	0.356	409	1573	1816	0.315	1.22 (1.10-1.36)	2.66 x 10 ⁻⁴		
	Combined ^e											1.30 (1.18-1.42)	1.28 x 10 ⁻⁸	0.029	
rs9405098															
	GWAS	a/g	No gene (6p21.3)	75	293	308	0.328	70	365	608	0.242	1.54 (1.30-1.84)	1.10 x 10 ⁻⁶		
	Replication			100	361	462	0.304	249	1429	2129	0.253	1.30 (1.16-1.46)	5.64 x 10 ⁻⁶		
	Combined ^e											1.37 (1.23-1.50)	1.04 x 10 ⁻¹⁰	0.105	
rs3135363															
	GWAS	c/t	No gene (6p21.3)	35	258	383	0.757	89	447	507	0.700	1.58 (1.32-1.90)	7.89 x 10 ⁻⁷		
	Replication			73	322	540	0.750	389	1486	1929	0.702	1.30 (1.16-1.46)	7.94 x 10 ⁻⁶		
	Combined ^e											1.37 (1.24-1.51)	1.45 x 10 ⁻¹⁰	0.069	
rs3129860															
	GWAS	a/g	No gene (6p21.3)	58	294	324	0.303	57	348	638	0.221	1.55 (1.29-1.82)	6.45 x 10 ⁻⁶		
	Replication			88	339	507	0.276	208	1341	2246	0.231	1.28 (1.14-1.44)	2.53 x 10 ⁻⁵		
	Combined ^e											1.36 (1.22-1.49)	1.07 x 10 ⁻⁹	0.085	

1618 (682 in GWAS and 936 in replication) liver cirrhosis and 4854 (1045 in GWAS and 3809 in replication) chronic hepatitis C samples were analyzed.

^aRAF, risk allele frequency.

^bOR, odds ratios; CI, confidence interval.

^c*p* Values obtained by logistic regression analysis adjusted for age and gender under additive model.

^d*p* Values of heterogeneities (Phet) across three stages were examined by using the Breslow-Day test.

^eCombined odds ratio and *p* values for independence test were calculated by Mendel-hauzen and Laird method in the meta-analysis.

Supplementary Fig. 3). To further evaluate the effect of each variation on the progression from CHC to LC, we performed multiple logistic regression analyses. As a result, rs910049 (*p* of 1.91×10^{-3} with OR of 1.25) and rs3135363 (*p* of 1.49×10^{-4} with OR of 1.23) remained significantly associated with the progression risk from CHC to LC, while the remaining three SNPs failed to show significant associations (*p* > 0.05) (Supplementary Table 3). Thus, two SNPs, rs910049 and rs3135363, seem to be independent risk factors for HCV-induced LC.

Since reduced platelet level is associated with a poor prognosis among CHC patients [44] we excluded patients with platelet level of less than 160,000 from CHC groups to increase the risk of type 2 error in this study. We also conducted the analysis using only CHC patients diagnosed with liver biopsy. As a result, both SNPs reached genome-wide significance (*p* < 5×10^{-8}), although the associations were reduced due to the smaller sample size (Supplementary Table 4).

Subgroup analyses, stratified by IFN treatment status, amount of alcohol consumption, and gender, were also performed, since these factors were shown to be associated with the prognosis of CHC patients [45–47]. A total of 334 LC patients (35.83%) and 2325 CHC (82.4%) were treated with IFN therapy. Although the frequency of IFN treatment was different between CHC and LC groups, these variations associated with the LC risk regardless of IFN treatment as well as gender and alcohol consumption (Supplementary Fig. 4A–C). When we included these factors as covariates, the association of these variations with HCV-induced LC was sustained, with OR of 1.48 and 1.56, and SNP rs3135363

still reached genome-wide significance (*p* = 3.95×10^{-9}) (Supplementary Table 5).

The association of previously reported variations with HCV-induced LC

Non-synonymous SNP rs738409 (I148M) in the *PNPLA3* gene was shown to be associated with progression of LC in the previous prospective study in Caucasians [31]. SNP rs738409 was also associated with the severity of non-alcoholic fatty liver disease in Japanese [48]. Therefore, we analyzed SNP rs738409 in our case-control cohort, but rs738409 did not significantly associate with HCV-induced LC (*p* = 0.24 and OR = 1.10), although the risk G allele was more frequent among LC than CHC (Supplementary Table 6). Our result is similar to what observed among Caucasians in the previous study, in which rs738409 increased liver cancer risk among alcoholic cirrhosis but did not among hepatitis C cirrhosis [49]. Since biological studies demonstrated that its risk allele (G) abolishes the triglyceride hydrolysis activity of *PNPLA3* [50] *PNPLA3* variation would have a strong impact on non-viral cirrhosis.

Recently, GWAS in the Caucasian population identified the association of SNPs rs4374383, rs16851720 and rs9380516 with the progression of liver fibrosis after HCV infection [51]. However, SNPs rs4374383 and rs16851720 did not exhibit significant association (*p* = 0.654 and 0.231, respectively) in our sample set. Although SNP rs9380516 exhibited the association with *p*-value of 0.015, the risk allele showed an opposite result

Table 3. Results of three associated variations from candidate gene analyses.

Gene	Tagging SNP	Haplotype frequency		OR (95% CI) ^a		<i>p</i> value ^b
		Liver cirrhosis	Chronic hepatitis C			
<i>DQA1*0601</i>	rs2736182(T) + rs2071293(A)	0.038	0.019	2.80	1.38-3.32	4.53×10^{-4}
<i>DRB1*0405</i>	rs411326(C) + rs2395185(A) + rs4599680(A)	0.324	0.266	1.45	1.15-1.56	1.54×10^{-4}

Association was tested by comparing haplotype distribution between 682 liver cirrhosis and 1045 chronic hepatitis C samples in GWAS.

^aOR, odds ratio; CI, confidence interval.

^b*p* Values were obtained by case-control analysis of GWAS stage (*p* for haplotype were obtained by score test, implemented in R) (*DQA1*0601* and *DRB1*0405*). The *p* values obtained by logistic regression analysis adjusted for age and gender under additive model.

(Supplementary Table 6). Taken together, these SNPs would not be associated with liver fibrosis in the Japanese population.

Genes related to extracellular matrix turnover or immune response (*KRT 19*, *COL1A1*, *STMN2*, *CXCL6*, *CCR2*, *TIMP1*, *IL8*, *IL1A*, *ITGA2*, *CLDN 4*, and *IL2*) were shown to be implicated in liver fibrosis of chronic hepatitis C [14]. To further characterize these loci, we conducted imputation analyses in the GWAS sample set (682 cases and 1045 controls), using data from HAPMAP phase II (JPT), and found 163 SNPs in 9 loci. However, none of these SNPs indicated significant association with *p*-value of less than 0.01 (Supplementary Table 7). Thus, variations of these genes did not associate with progression from chronic hepatitis C to liver cirrhosis.

Imputation-based fine mapping of HLA region

The most significantly associated SNP rs3135363 is located within an intergenic region between *BTNL2* and *HLA-DRA*, and rs910049 is located in intron 7 of *C6orf10* gene (Supplementary Figs. 5 and 6). To further characterize these loci, we conducted imputation-based association analysis for the GWAS samples (682 LC and 1045 CHC samples) using data from HAPMAP Phase II (JPT), and could obtain the results of nearly 6000 SNPs in a 4-Mb genomic region. The regional association plots revealed that all modestly-associated SNPs are confined within a 700-kb region containing 21 genes, namely *TNXB*, *ATF6B*, *FKBP1*, *PRRT1*, *PPT2*, *EGFL8*, *AGPAT1*, *RNF5*, *RNF5P1*, *AGER*, *PBX2*, *C6orf10*, *BTNL2*, *HLA-DRA*, *HLA-DRB5*, *HLA-DRB6*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DQB1* and *HLA-DQB2* (Supplementary Fig. 5). Although 640 SNPs, including ten non-synonymous SNPs within the 4-Mb region, showed very modest associations ($p < 0.01$) with HCV-induced LC, none of these SNPs in this region revealed strong association with HCV-induced LC, after adjustment with the two SNPs, rs910049 and rs3135363 (Supplementary Fig. 7). Taken together, the associations observed in this region would reflect the association with rs910049 and rs3135363.

Previous reports indicated the association of *HLA-DRB1* and *HLA-DQ* alleles with HCV-induced chronic hepatitis in the Japanese population [26]. To investigate the association of HLA alleles with HCV-induced LC, we estimated the genotypes at the HLA region by applying the imputation results of HLA-tagging SNPs [37]. We could successfully determine 53 alleles of *HLA-A*, *B*, *C*, *DQA*, *DQB*, and *DRB* genes and find that *HLA-DQA1*0601* and *HLA-DRB1*0405* were strongly associated with HCV-induced LC (*p* values of 4.53×10^{-4} and 1.54×10^{-4} with ORs of 2.80 and 1.45) even after the Bonferroni correction ($p < 0.05/53 = 9.43 \times 10^{-4}$) (Table 3 and Supplementary Table 8A-E) [37].




Fig. 2. Cumulative effects of liver cirrhosis risk alleles. (A) Frequency distribution divided by risk allele numbers (rs910049, rs3135363, and *HLA-DQA1*0601*) among liver cirrhosis (light blue bars) and chronic hepatitis C (dark blue bars) patients. (B) Plot of the increase odds ratio (OR) for liver cirrhosis according to the number of risk alleles. The ORs are relative to the subjects with no risk alleles (rs910049, rs3135363, and *HLA-DQA1*0601*). Vertical bars correspond to 95% confidence intervals. Horizontal line marks the null value (OR = 1).

Cumulative effect of multiple loci within the HLA region

SNPs rs3135363 and rs910049, *HLA-DQA1*0601*, and *HLA-DRB1*0405* are located within a 300-kb segment in the HLA class II region and show moderate linkage disequilibrium (Supplementary Fig. 8). To further evaluate these genetic factors, we performed multiple logistic regression analyses and found that rs910049 (p of 9.40×10^{-3} with OR of 1.38), rs3135363 (p of 3.94×10^{-4} with OR = 1.41), and *HLA-DQA1*0601* (p of 7.79×10^{-3} with OR of 1.54) were significantly associated with HCV-induced LC (Supplementary Table 9), indicating these three variations were independent risk factors for progression of CHC to LC.

To investigate the pathophysiological roles of rs910049 and rs3135363 in disease progression, we searched the eQTL database (<http://www.sph.umich.edu/csg/liang/imputation>) and found that risk alleles of rs910049 (A) and rs3135363 (T) were associated with lower expression of *HLA-DQA* (LOD of ≥ 6.86 and 17.31, respectively) and *DRB1* (LOD of ≥ 12.01 and 18.96, respectively), and with higher expression of *HLA-DQB1* (LOD of ≥ 6.76 and 4.46, respectively) (Supplementary Table 10). Thus, rs910049 and rs3135363 are likely to affect the expression of HLA class II molecules and subsequently alter the risk of HCV-induced LC.

Finally, we examined the cumulative effects of rs910049, rs3135363, and *HLA-DQA1*0601*. Individuals with four or more risk alleles (8.8% of general population) have 2.83-fold higher risk of HCV-induced LC compared with those with no risk allele (15.0% of general population, Fig. 2).

Research Article

Discussion

We here demonstrated that multiple genetic variations in the MHC region were significantly associated with the risk of disease progression from CHC to LC, using a total of 1618 HCV-LC and 4854 CHC cases. Since a substantial proportion of patients with CHC show progression to LC in a certain time period, exclusion of CHC patients who have a high risk for LC from control subjects is essential to reduce the risk of false negative association. In this study, CHC patients with advanced fibrosis (F3 or F4 in stage) or with reduced platelet level (less than 160,000/ μ l) were excluded from the control samples, since these alterations are well-known risk factors for LC development [9,32]. Consequently, we were successfully able to identify the HCV-induced LC loci.

HLA genes are known to play critical roles in the regulation of our immune responses through controlling the antigen presentation to CD8 (class I) and CD4 (class II) T cells. Although previous studies indicated the association of HLA class I alleles such as *HLA-B57*, *HLA-A11*, and *HLA-C04* with persistent HCV infection [52,53], no SNPs in the HLA class I region exhibited strong association with HCV-induced LC. Here we identified three variations (rs910049, rs3135363, *HLA-DQA1*0601*) in the HLA class II region to be significantly associated with the progression risk from CHC to LC. Since two SNPs, rs910049 and rs3135363, had been indicated to affect expression levels of *HLA-DRB1* and *DQ*, our findings indicated the significant pathophysiological roles of HLA class II molecules in the development of HCV-induced liver fibrosis. Considering the function of *HLA-DQ* and *HLA-DR*, we suggest that the antigen presentation by HLA class II molecules is likely to play a critical role in the elimination of HCV-infected liver cells and subsequently prevent HCV-induced LC.

Direct acting antiviral drugs for HCV can cure up to 75% of patients infected with HCV genotype 1, and the lifetime risk of developing LC and HCC among HCV carriers was decreased during the two recent decades [54,13]. However, the amino acid sequence of the NS3 protease domain varies significantly between HCV genotypes and the antiviral efficacy differs in different HCV genotypes [55]. Moreover, protease inhibitors increased the incidence of adverse reactions such as anemia and skin rash [56]. Therefore, estimation of liver cirrhosis risk and prediction of treatment response would be essential to provide a personalized treatment and to achieve the optimal results. Due to the recent advances in pharmacogenetic studies, genetic factors associated with efficacy and adverse effects of anti-HCV treatment were identified. *IL-28B* is a powerful predictor of treatment outcome of pegylated interferon and ribavirin therapy [22], while a genetic variation in the *ITPA* gene was shown to be associated with ribavirin-induced anemia [57]. Since we conducted a retrospective study, and the majority of LC patients did not receive IFN treatment, we could not evaluate the treatment responses in our study design. However, SNPs identified in this study were associated with the LC risk independent of IFN treatment. Although the impact of each SNP was relatively weak compared with viral factors (HCV genotype, core and NS5A mutation [58]) and host factors (age, gender, obesity, and insulin resistance), we found that individuals with three or more risk alleles have a nearly three-fold higher risk of LC than those with no risk allele. Since lifetime risk of HCC development among HCV carriers is as high as about 27% for male and 8% for female [59], these three loci would have the strong effect on the clinical outcome of CHC patients. In general, the progression from chronic hepatitis C to liver cirrhosis usually takes more than 20–30 years. Therefore,

a large scale prospective cohort study with more than 10-year follow-up is essential to evaluate the role of these variations as a prognostic biomarker. We would like to perform prospective analysis in future studies. We hope that our findings would contribute to clarify the underlying molecular mechanism of HCV-induced liver cirrhosis.

Financial support

This work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Authors' contributions

Y. U., K. K., K. C., and K.M. conceived and designed the study; Y. U., H. O., N. K., Y. K., R. M., N. H., and M. K. performed genotyping; A. T., P. H. Y. L., C. T., and N. K. performed quality control at genome-wide phase; M. O., R. T., M. O., K. K., D. M., H. A., J. T., H. K., Y. N., K. M. and M. K. managed DNA samples; Y. U. analyzed and summarized the whole results; Y. U., Y. N., and K. M. wrote the manuscript; Y. N. obtained funding for the study.

Acknowledgments

We thank Ayako Matsui and Hiroe Tagaya (the University of Tokyo), and the technical staff of the Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN, for their technical support.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jhep.2012.12.024>.

References

- [1] Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005;5:558–567.
- [2] Seeff LB. Natural history of chronic hepatitis C. *Hepatology* 2002;36:S35–S46.
- [3] Thomas DL, Seeff LB. Natural history of hepatitis C. *Clin Liver Dis* 2005;9:383–398, vi.
- [4] Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001;34:809–816.
- [5] Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. *Hepatology* 1997;26:155–205.
- [6] Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. *Ann Intern Med* 2008;148:820–826.

JOURNAL OF HEPATOLOGY

- [7] Global burden of disease (GBD) for hepatitis C. *J Clin Pharmacol* 2004;44:20–29.
- [8] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349:825–832.
- [9] Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. *Ann Intern Med* 1999;131:174–181.
- [10] Zhang Q, Tanaka K, Sun P, Nakata M, Yamamoto R, Sakimura K, et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. *Neurobiol Dis* 2012;45:610–615.
- [11] Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, et al. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. *Hepatology* 2012;56:549–556.
- [12] Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. *Virology* 2005;332:130–144.
- [13] Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. *J Hepatol* 2012;57:1110–1125.
- [14] Asselah T, Bièche I, Laurendeau I, Paradis V, Vidaud D, Degott C, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2005;129:2064–2075.
- [15] Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. *Lab Invest* 2010;90:1727–1736.
- [16] Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, Ninomiya M, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. *Liver Int* 2011;31:474–484.
- [17] Cui R, Okada Y, Jang SG, Ku JL, Park JG, Kamatani Y, et al. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. *Gut* 2011;60:799–805.
- [18] Kumar V, Matsuo K, Takahashi A, Hosono N, Tsunoda T, Kamatani N, et al. Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility. *J Hum Genet* 2011;56:436–439.
- [19] Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, Ito H, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. *Nat Genet* 2012;44:430–434.
- [20] Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, et al. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible loci at 5q35.3, 7p14.3, and 13q14.1. *PLoS Genet* 2012;8:e1002541.
- [21] Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009;461:798–801.
- [22] Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105–1109.
- [23] Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009;41:1100–1104.
- [24] Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* 2011;43:455–458.
- [25] Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, et al. Variation in the DEPC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. *Nat Genet* 2011;43:797–800.
- [26] Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. *Hepatology* 1998;27:240–244.
- [27] Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. *World J Gastroenterol* 2007;13:1770–1787.
- [28] Mosaad YM, Farag RE, Arafat MM, Eletreby S, El-Alfy HA, Eldeek BS, et al. Association of human leucocyte antigen Class I (HLA-A and HLA-B) with chronic hepatitis C virus infection in Egyptian patients. *Scand J Immunol* 2010;72:548–553.
- [29] Li CZ, Kato N, Chang JH, Muroyama R, Shao RX, Dharel N, et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. *Liver Int* 2009;29:1413–1421.
- [30] Mozer-Lisewska I, Sikora J, Kowala-Piaskowska A, Kaczmarek M, Dworacki G, Zeromski J. The incidence and significance of pattern-recognition receptors in chronic viral hepatitis types B and C in man. *Arch Immunol Ther Exp (Warsz)* 2010;58:295–302.
- [31] Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. *Hepatology* 2011;54:60–69.
- [32] Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, et al. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. *Hepatology* 2008;47:810–816.
- [33] Nakamura Y. The BioBank Japan project. *Clin Adv Hematol Oncol* 2007;5:696–697.
- [34] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559–575.
- [35] Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* 2007;449:851–861.
- [36] Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies. *IARC Sci Publ* 1987;11:1–406.
- [37] de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet* 2006;38:1166–1172.
- [38] Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 2007;316:1341–1345.
- [39] Consortium GP. A map of human genome variation from population-scale sequencing. *Nature* 2010;467:1061–1073.
- [40] Barrett J, Fry B, Maller J, Daly M. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263–265.
- [41] Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res* 2009;37:W600–W605.
- [42] Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, et al. A genome-wide association study of global gene expression. *Nat Genet* 2007;39:1202–1207.
- [43] Kel AE, Gössling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. *Nucleic Acids Res* 2003;31:3576–3579.
- [44] Wai CT, Greenon JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;38:518–526.
- [45] Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. *Hepatology* 2004;39:333–342.
- [46] Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002;36:S47–S56.
- [47] Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. *Gastroenterology* 1996;111:199–205.
- [48] Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012;7:e38322.
- [49] Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. *PLoS One* 2011;6:e27087.
- [50] He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem* 2010;285:6706.
- [51] Patin E, Kutalik Z, Guernon J, Bibert S, Nalpas B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012;143:124–152, e1–12.
- [52] Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyrol LL, et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. *Gastroenterology* 2011;140:e681.
- [53] Fanning LJ, Kenny-Walsh E, Shanahan F. Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class I. *Hum Immunol* 2004;65:745–751.

Research Article

- [54] Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). *Hepatology* 2011;53:1090–1099.
- [55] Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. *Liver Int* 2012;32: 88–102.
- [56] Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. *J Gastroenterol* 2011;46:929–937.
- [57] Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy – a genome-wide study of Japanese HCV virus patients. *Gastroenterology* 2010;139:1190–1197.
- [58] Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996;334:77–82.
- [59] Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. *J Clin Oncol* 2011;29:3643–3650.

Identification of a Functional Variant in the *MICA* Promoter Which Regulates *MICA* Expression and Increases HCV-Related Hepatocellular Carcinoma Risk

Paulisally Hau Yi Lo¹, Yuji Urabe^{1,2}, Vinod Kumar¹, Chizu Tanikawa¹, Kazuhiko Koike³, Naoya Kato⁴, Daiki Miki^{2,5}, Kazuaki Chayama^{2,5}, Michiaki Kubo⁵, Yusuke Nakamura^{1,6}, Koichi Matsuda^{1*}

1 Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, **2** Departments of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, **3** Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, **4** Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, **5** Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan, **6** Departments of Medicine and Surgery, and Center for Personalized Therapeutics, The University of Chicago, Chicago, Illinois, United States of America

Abstract

Hepatitis C virus (HCV) infection is the major cause of hepatocellular carcinoma (HCC) in Japan. We previously identified the association of SNP rs2596542 in the 5' flanking region of the *MHC class I polypeptide-related sequence A* (*MICA*) gene with the risk of HCV-induced HCC. In the current study, we performed detailed functional analysis of 12 candidate SNPs in the promoter region and found that a SNP rs2596538 located at 2.8 kb upstream of the *MICA* gene affected the binding of a nuclear protein(s) to the genomic segment including this SNP. By electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay, we identified that transcription factor Specificity Protein 1 (SP1) can bind to the protective G allele, but not to the risk A allele. In addition, reporter construct containing the G allele was found to exhibit higher transcriptional activity than that containing the A allele. Moreover, SNP rs2596538 showed stronger association with HCV-induced HCC ($P = 1.82 \times 10^{-5}$ and OR = 1.34) than the previously identified SNP rs2596542. We also found significantly higher serum level of soluble MICA (sMICA) in HCV-induced HCC patients carrying the G allele than those carrying the A allele ($P = 0.00616$). In summary, we have identified a functional SNP that is associated with the expression of *MICA* and the risk for HCV-induced HCC.

Citation: Lo PHY, Urabe Y, Kumar V, Tanikawa C, Koike K, et al. (2013) Identification of a Functional Variant in the *MICA* Promoter Which Regulates *MICA* Expression and Increases HCV-Related Hepatocellular Carcinoma Risk. PLoS ONE 8(4): e61279. doi:10.1371/journal.pone.0061279

Editor: Erica Villa, University of Modena & Reggio Emilia, Italy

Received: September 24, 2012; **Accepted:** March 11, 2013; **Published:** April 11, 2013

Copyright: © 2013 Lo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government, the Ministry of Health, Labour, and Welfare of the Japanese government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: koichima@ims.u-tokyo.ac.jp

Introduction

Hepatocellular carcinoma (HCC) is one of the common cancers in the world. It is well-known to be associated with the chronic infection of Hepatitis B (HBV) and Hepatitis C (HCV) viruses. In Japan, nearly 70% of HCC patients are infected with HCV [1]. The annual rate of developing HCC among patients with HCV-related liver cirrhosis in Japan is estimated to be about 4–8 percent [2]. Recent analyses have identified various genetic factors that are related with viral induced liver diseases [3–5]. In our previous two-stage genome-wide association study (GWAS) using a total number of 1,394 cases and 5,486 controls, a SNP rs2596542 located on chromosome 6p21.33 was shown to be significantly associated with HCV-induced HCC ($P = 4.21 \times 10^{-13}$ and OR = 1.39) [6]. This SNP is located within the class I major histocompatibility complex (MHC) region and is at about 4.8 kb upstream of *MHC class I polypeptide-related sequence A* (*MICA*) gene. We also identified that the risk A allele of SNP rs2596542 was strongly associated with the low expression of soluble MICA (sMICA) in the serum of HCV-related HCC patients [6].

MICA is a membrane protein which is up-regulated in various tumor cells and also induced in response to various cellular stresses such as infection, hypoxia, and heat shock [7]. It is an important component of the innate immune response, as *MICA* can bind to the NKG2D receptor and subsequently activate natural killer (NK) cells, CD8+ cells, and $\gamma\delta$ T cells [8,9]. Moreover, membrane *MICA* can be shed by metalloproteinases, including MMP9, ADAM10, and ADAM17, and secreted into serum as a soluble form [10,11]. Since these metalloproteinases are often activated in HCC, the expressions of both membrane-bound *MICA* and sMICA are increased [12,13]. SNP rs2596542 was found to be associated with the progression from chronic hepatitis C (CHC) to HCC and also with serum sMICA level. Hence, both rs2596542 and sMICA would be possible prognostic biomarkers for CHC patients. However, their underlying molecular mechanisms were not fully elucidated so far.

We hypothesize that *MICA* variations could affect sMICA level by either one or both of the following two possible mechanisms: (1) the genetic variation(s) in the coding region affecting the protein stability and (2) the transcriptional regulation. Previously, variable

numbers of tandem repeats (VNTRs) in exon 5 of *MICA* were identified to affect *MICA* subcellular localization and serum *MICA* level [14]. The exon 5 of *MICA* encodes the transmembrane domain and the insertion of an extra G nucleotide in the domain would result in a premature stop codon that would generate *MICA* protein without a transmembrane domain and subsequently affect s*MICA* level [14]. However, our previous results indicated that *MICA* VNTR was not significantly associated with the s*MICA* level or HCC risk [6]. Therefore, in the current study, we have tried to investigate whether the *MICA* variations would affect the *MICA* transcription in the liver cancer cells. Through the functional analysis of genetic variations in the *MICA* promoter region, we here report a causative SNP rs2596538 that increases the binding affinity of the transcription factor Specificity Protein 1 (SP1) and the risk of progression of the disease.

Materials and Methods

Samples and genotyping

DNA samples for direct sequencing (50 HCV-related HCC cases), imputation analysis (721 HCV-related HCC cases and 5,486 HCV-negative controls), and serum samples for s*MICA* ELISA (246 HCV-related HCC) were obtained from BioBank Japan [15,16]. Genotyping of SNPs from 1,394 HCC patients and measurement of s*MICA* expression by ELISA were performed in the previous study [6]. Genotyping of SNP rs2596542 in 1,043 CHC was performed previously in RIKEN using Illumina HumanHap610-Quad BeadChip [17]. All CHC subjects had abnormal levels of serum alanine transaminase for more than 6 months and were positive for both HCV antibody and serum HCV RNA. The SNP rs2596542 in liver cirrhosis samples without hepatocellular carcinoma from BioBank Japan ($n = 420$) and the University of Tokyo ($n = 166$) were genotyped using Illumina HumanHap610-Quad BeadChip or invader assay [18]. All subjects were either subjected to liver biopsy or diagnosed by non-invasive methods including hepatic imaging, biochemical data, and the presence/absence of clinical manifestations of portal hypertension [18]. The samples used in the current project were listed in Table S1. Case samples with HBV co-infection were excluded from this study. The subjects with cancers, chronic hepatitis B, diabetes or tuberculosis were excluded from non-HCV controls. All subjects were Japanese origin and provided written informed consent. This research project was approved by the ethical committees of the University of Tokyo and RIKEN.

Imputation study

The imputation study was performed by using a hidden Markov model programmed in MACH [19] and haplotype information from 1000 genomes database [20]. The imputation results were confirmed by direct DNA sequencing in 50 randomly selected samples.

Cell culture

Human liver cancer cell lines HLE and HepG2 were purchased from JHSF (Osaka, Japan) and ATCC. These cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) with 10% fetal bovine serum. Cells were cultured at 37°C with 5% CO₂.

EMSA

HLE cells were grown in 15 cm culture plate until they reached 95% confluency. The plate was then sealed with parafilm and immersed in a water bath at 42.5°C for 1.5 hours [21]. Nuclear extracts from these cells were prepared according to the standard

protocol [22]. EMSA was carried out using DIG Gel Shift Kit, 2nd Generation (Roche) according to the manufacturer's instructions. The sequences of the 12 probes were listed in the Table S2. In brief, 30 fmol of labeled probes were hybridized with 5 µg nuclear extract for 15 minutes at room temperature. The mixtures were then loaded into a 6% TBE gel, separated by electrophoresis at 4°C and transferred onto a nylon membrane. The membrane was then hybridized with anti-digoxigenin-AP antibody and developed by CSPD solution. For competition study, nuclear extracts were incubated with non-labeled oligonucleotides first before adding labeled probe. For supershift assay, SP1 antibody (SC-59X, Santa Cruz Biotechnology) was added into the nuclear extract and incubated on ice for 30 minutes first before adding labeled probe. The mixtures were then separated by electrophoresis using 4% TBE gel. All EMSAs were repeated twice for reconfirmation of the results.

ChIP

The HLE cells (G allele homozygote) and HepG2 cells (heterozygote) were used in the ChIP assay. The plasmid pCAGGS-SP1 was transfected into both cells by using FuGENE6 Transfection Reagent (Roche). The ChIP assays were carried out using Chromatin Immunoprecipitation Assay Kit (Millipore) according to the manufacturer's protocol. In brief, the cells were treated with formaldehyde to crosslink DNA-protein complexes at 48 hours post-transfection. DNA-protein complexes were then sheared by sonication and immunoprecipitated by rabbit polyclonal anti-SP1 antibody (SC-59X, Santa Cruz Biotechnology). The resulting DNAs were analyzed by PCR (Table S2). In order to determine the binding specificity of SP1 to the SNP rs2596538 allele, the PCR products from HepG2 cells were further sub-cloned into pCR 2.1 vector and sequenced to assess G to A ratio in both input DNA and immunoprecipitant.

Dual luciferase reporter assay

Three copies of 31 bp DNA fragments equivalent to the EMSA oligonucleotides of SNP rs2596538 were cloned into pGL3-promoter vector (Promega). The plasmids were co-transfected with pCAGGS-SP1 and pRL-TK plasmids (Promega) into HLE cells by FuGENE6 Transfection Reagent (Roche). The pCAGGS-SP1 plasmid provided the expression of transcription factor SP1, and pRL-TK plasmid served as internal control for transfection efficiency [23]. The cells were lysed at 48 hours post-transfection, and relative luciferase activities were measured by Dual Luciferase Assay System (Toyo B-Net).

Western blotting

Cancer cell lysates were prepared by using pre-chilled RIPA buffer, and 25 µg of each lysate was loaded into the gel and separated by SDS-PAGE. Western blotting was performed according to the standard protocol. Rabbit anti-MICA antibody (ab63709, abcam: 1/1000) and rabbit anti-SP1 antibody (17-601, Upstate Biotechnology: 1/500) were used in the experiment.

Statistical analysis

The case-control association was analyzed by Student's *t*-test and Fisher's exact test as appropriate. The association of allele dependent s*MICA* expression was studied by Kruskal-Wallis test using R statistical environment version 2.8.1. The LD and coefficients (D' and r^2) were calculated by Haploview version 4.2 [24].

Table 1. Association of rs2596542 with the progression from CHC to LC and HCC.

	Case MAF	Control MAF	P ^a	OR	95% C.I.
LC vs CHC	0.3797	0.3442	0.04842	1.166	1.01–1.35
HCC vs LC	0.4012	0.3797	0.20296	1.094	0.95–1.26

MAF, minor allele frequency; OR, odds ratio for minor allele. C.I., confidence interval. SNP rs2596542 was analyzed in 1,043 chronic hepatitis C (CHC), 586 liver cirrhosis without hepatocellular carcinoma (LC) and 1,394 HCV-induced hepatocellular carcinoma patients (HCC). ^acalculated by Armitage trend test. doi:10.1371/journal.pone.0061279.t001

Results

Analyses of SNP rs2596542 in HCV-infected patients at different disease stages

Since the development of HCC consists of multiple steps, we investigated the role of SNP rs2596542 with disease progression. SNP rs2596542 was genotyped in patients at three different disease categories of CHC (chronic hepatitis C) without liver cirrhosis (LC) or HCC, LC without HCC, and HCC. The statistical analysis indicated that SNP rs2596542 was significantly associated with disease progression from CHC to LC with P-value of 0.048 and odds ratio of 1.17 (Table 1). The risk allele frequency among HCC patients (40.1%) was higher than that among LC patients (38.0%), but the association was not statistically significant (P-value of 0.203 and odds ratio of 1.09). These results suggested the involvement of *MICA* with both liver fibrosis and hepatocellular carcinogenesis.

HCV-HCC risk is not associated with *MICA* copy number variation

A previous report has indicated the deletion of the entire *MICA* locus in 3.2% of Japanese population [25] and this deletion was shown to be associated with the risk of nasopharyngeal carcinoma (NPC), especially in male [26]. To identify the functional SNP that may affect *MICA* mRNA expression, we analyzed the relation between the *MICA* copy number variation (CNV) and the HCC

susceptibility. We quantified this CNV by real-time PCR in 375 HCV-related HCC patients and 350 HCV-negative controls. As shown in Table S3, we found no difference in the copy numbers between HCC cases and controls, indicating that this CNV is unlikely to be causative genetic variation for the risk of HCC.

Direct sequencing of 5' flanking region of *MICA*

We then focused on the variations in the 5' flanking region of the *MICA* gene which may be associated with its promoter activity. We had conducted direct DNA sequencing of the 5-kb promoter region which included the marker SNP rs2596542 using genomic DNAs of 50 HCC subjects and identified 11 SNPs showing strong linkage disequilibrium with the marker SNP rs2596542 ($D' > 0.953$ and $r^2 > 0.832$) (Fig. S1, Table 2).

Allele specific binding of nuclear protein to genomic region including SNP rs2596538


To investigate whether these genetic variations would affect the binding affinity of some transcription factors, we had conducted the electrophoretic mobility shift assay (EMSA) using the nuclear extract of HLE human hepatocellular carcinoma cells. Since *MICA* is a stress-inducible protein [21], we first treated the cells with heat shock treatment at 42°C for 90 minutes and confirmed significant induction of *MICA* expression as shown in Fig. 1a. Then we performed EMSA using 24 labeled-oligonucleotides corresponding to each allele of the 12 candidates' SNPs. The results of EMSA demonstrated that an oligonucleotide corresponding to a G allele of SNP rs2596538 exhibited stronger binding affinity to a nuclear protein(s) than that to an A allele (Fig. 1b). We then confirmed the specific binding of nuclear proteins to the G allele by competitor assay using non-labeled oligonucleotides (Fig. 1c). The self (G allele) oligonucleotides inhibited the formation of DNA-protein complex in a dose-dependent manner, but the non-self (A allele) oligonucleotides showed no inhibition effect. Taken together, some nuclear protein(s) in hepatocellular carcinoma cells would interact with a DNA fragment including the G allele of SNP rs2596538.

Table 2. Linkage disequilibrium between 11 candidate SNPs and SNP rs2596542.


SNP ID	Relative position ^a	A1	A1 frequency	D'	r ²
rs2596542	−4815	A	0.36		
rs2428475	−4788	G	0.36	1	1
rs28366144	−4586	T	0.36	1	1
rs2428474	−4387	G	0.39	1	0.88
rs2251731	−4045	A	0.39	1	0.88
rs2844526	−3703	C	0.38	1	0.918
rs2596541	−3572	A	0.38	1	0.918
rs2523453	−3285	G	0.38	1	0.918
rs2544525	−3259	C	0.38	1	0.918
rs2523452	−2870	G	0.34	0.953	0.832
rs2596538	−2778	A	0.34	0.953	0.832
rs2844522	−2710	C	0.34	0.953	0.832

Note: Direct DNA sequence of 5-kb promoter region of *MICA* from 50 HCV-HCC subjects. D' and r² were calculated by comparing the genotypes of these SNPs to the marker SNP rs2596542 by Haploview. A1, minor allele; ^aRelative position to exon 1 of the *MICA* gene. doi:10.1371/journal.pone.0061279.t002

a



b



c




Figure 1. SNP rs2596538 affects the binding affinity of nuclear proteins. (A) Real-time quantitative PCR (upper) and Western blotting (lower) of MICA before and after heat shock treatment in HLE cells. *B2M* and β -actin are served as internal and protein loading control. (B) EMSA using 31 bp labeled probes flanking each SNP located within the 4.8 kb region upstream of *MICA* transcription start site. A black arrow indicates the shifted band specific to G allele of SNP rs2596538. (C) EMSA using the labeled G allele of SNP rs2596538 and nuclear extract from heat treated HLE cells. Non-labeled A or G allele of SNP rs2596538 at different concentrations are used as competitors. Pointed arrow indicates shifted band. * $P < 0.05$ by Student's *t*-test.

doi:10.1371/journal.pone.0061279.g001




Figure 2. Binding of transcription factor SP1 to G allele of SNP rs2596538. (A) Multiple alignment of a GC box and DNA sequence of A or G probe of SNP rs2596538 used in EMSA. (B) EMSA using the labeled G allele of SNP rs2596538 and nuclear extract from heat treated HLE cells. Non-labeled consensus oligonucleotides of seven transcription factors are used as competitors. Pointed arrow indicates shifted band. (C) EMSA using the labeled G allele of SNP rs2596538 and nuclear extract from heat shock treated HLE cells in the presence of anti-SP1 antibody or normal rabbit IgG. Asterisks on the left side indicate the shifted (*) and super-shifted bands (**). Normal rabbit IgG serves as a negative control. (D) ChIP assay using HepG2 and HLE cell lines were ectopically expressed with SP1 protein. DNA-protein complex was immunoprecipitated with anti-SP1 antibody followed by PCR amplification using a primer pair flanking SNP rs2596538. DNAs precipitated without antibody are served as a negative control. PCR primers flanking the 3' UTR region of *MICA* are served as a negative control. (E) Genotype distribution at SNP rs2596538 in PCR fragment amplified from the input genomic DNA and DNA-protein complex immunoprecipitated from HepG2 cells by using anti-SP1 antibody. * $P < 0.05$ by Student's *t*-test. doi:10.1371/journal.pone.0061279.g002

SNP rs2596538 regulates the binding of SP1

Since *in silico* analysis identified a putative GC box in a protective G allele but not in a risk A allele (Fig. 2a), the transcription factor SP1 might preferentially bind to the G allele. Based on this information, we further performed competitor assay using non-labeled oligonucleotides (Table S2) and found that among seven tested oligonucleotides, only SP1-consensus oligonucleotides could effectively inhibit the binding of the nuclear protein(s) to the labeled G allele (Fig. 2b). In addition, we identified that the addition of anti-SP1 antibody caused a supershift of a band corresponding to the DNA-protein complex while control IgG did not cause the band shift (Fig. 2c). This result clearly indicated that the SP1 protein is very likely to be a component of the DNA-protein complex.

Furthermore, we performed chromatin immunoprecipitation (ChIP) assay to confirm the binding of SP1 to this genomic region *in vivo*. We had used two cell lines with different genetic backgrounds at SNP rs2596538 locus: HLE cells carrying the only G allele, while HepG2 cells harboring both A and G alleles. After the introduction of SP1 expression vector (pCAGGS-SP1) into these cell lines, the cell extracts were subjected to ChIP assay using anti-SP1 antibody (Fig. 2d). Subsequent PCR experiments indicated that SP1 bound to a genomic fragment containing the G

allele of SNP rs2596538 *in vivo*, while 3' UTR region of *MICA* (negative control) was not immunoprecipitated with anti-SP1 antibody. To further evaluate the binding ability of SP1 to each allele *in vivo*, we sub-cloned the DNA fragment that amplified from genomic DNA of HepG2 cells before and after immunoprecipitation by anti-SP1 antibody. The subsequent sequencing results showed that 26 out of 29 tested clones contained the G allele, demonstrating the preferential binding of SP1 to the G allele (Fig. 2e).

SP1 over-expression preferentially up-regulates *MICA* expression at G allele

To further investigate the physiological role of the interaction between SP1 and this genomic region, we performed reporter gene assay. Three copies of 31-bp DNA fragments flanking the candidate functional SNP rs2596538 were subcloned into the multiple cloning sites of the pGL3 promoter vector. The relative luciferase activity of the plasmid including the G allele was significantly higher than that including the A allele (Fig. 3a). Furthermore, over-expression of SP1 in the cells could significantly enhance the luciferase activity of the G-allele vector, while the enhancement of the A-allele vector was relatively modest (Fig. 3a).




Figure 3. Transcriptional regulation of *MICA* by SP1 through genomic region including SNP rs2596538. (A) Reporter assay using constructs including 3 copies of 31 bp DNA fragment flanking SNP rs2596538. Reporter constructs are transfected into HLE cells with pRL-TK and pCAGGS or pCAGGS-SP1 vector. The value of relative luciferase activity was calculated as the firefly luciferase intensity divided by the renilla luciferase intensity. The data represent the mean $\pm$ SD value of 4 independent studies. (* $P < 0.05$, Student's *t*-test) (B) *MICA* expression in HLE cells after transfection with pCAGGS or pCAGGS-SP1 vector. β -actin is served as a protein loading control.

doi:10.1371/journal.pone.0061279.g003

We also evaluated the effect of ectopically expressed SP1 on the *MICA* expression in HLE cells. Western-blot analysis showed that *MICA* protein expression was significantly increased after the SP1 over-expression (Fig. 3b). These results provided a strong evidence that the G allele has higher transcriptional potential that can be inducible by SP1.

Association of SNP rs2596538 with HCC risk and sMICA level in HCV-induced HCC patients

To further investigate the role of SNP rs2596538 in human carcinogenesis, we investigated the association of SNP rs2596538 with HCV-induced HCC in 721 HCV-HCC cases and 5,486 HCV-negative controls that had been genotyped using Illumina HumanHap610-Quad Genotyping BeadChip in our previous

study [6]. We performed imputation analysis by using haplotype data from 1000 genome database [20] and found that an A allele of SNP rs2596538 was considered to be a risk allele for HCV-related HCC (Table 3, odds ratio = 1.343, $P = 1.82 \times 10^{-5}$). The functional SNP rs2596538 exhibited a stronger association with the HCC risk than the marker SNP rs2596542 (2.46×10^{-5}). We also analyzed the relationship between the SNP rs2596538 and the sMICA level among 246 HCV-induced HCC patients and found a significant association with the P-value of 0.00616 (Fig. 4). These results were concordant with our functional analyses in which the G allele exhibited a higher affinity to SP1 and revealed a higher transcriptional activity.

Discussion

Approximately 160 million people (2.35% of the worldwide population) are estimated to have HCV infection [27]. Since HCV carriers have an increased risk to develop liver cirrhosis and subsequent HCC [28,29], the prediction of cancer risk is especially important for CHC patients. In our previous study, we have identified that SNP rs2596542 located in the upstream of *MICA* gene was significantly associated with the risk of HCC development among CHC patients as well as the serum level of sMICA [6]. In this study, we found that the genetic variant at SNP rs2596538 strongly affected the binding affinity of SP1. Over-expression of SP1 remarkably induced *MICA* expression in cells carrying the G allele that has a higher affinity to the SP1 binding. These findings are concordant with higher serum sMICA level among HCC patients with the G allele at SNP rs2596538. SP1 is a

Table 3. Association of SNP rs2596542 and SNP rs2596538 with HCV-induced HCC.

SNP ID	Relative position ^a	A1	OR	P value
rs2596542	-4815	A	1.339	2.46×10^{-5}
rs2596538	-2778	A	1.343	1.82×10^{-5}

Note: Genotype data of 721 HCV-HCC cases and 5,486 HCV-negative controls were imputed using 1000 genomes as reference. A1, risk allele; OR, odds ratio for the risk allele calculated by considering the protective allele as a reference.

^aRelative position to exon 1 of the *MICA* gene.

doi:10.1371/journal.pone.0061279.t003




Figure 4. Association between the soluble MICA levels and SNP rs2596538 genotype. The samples were classified into 3 groups according to rs2596538 genotype. The sMICA levels measured by ELISA are indicated in y-axis. The numbers of samples and the proportion of sMICA positive subjects from each group are shown in x-axis. The percentage of the positive sMICA expression in each group are AA = 10%, AG = 39%, and GG = 42%. Statistical significance was determined by Kruskal-Wallis test. doi:10.1371/journal.pone.0061279.g004

ubiquitously expressed transcription factor which binds to the GC-rich decanucleotide sequence (GC box) and activates the transcription of various viral and cellular genes [30,31]. Phosphorylation of SP1 was shown to be induced by HCV core protein and exhibited higher binding affinity to the promoter region of its downstream targets [32]. From our previous study, we showed a significant difference of sMICA expression between non-HCV individuals and CHC patients. This indicated that sMICA expression was induced after HCV infection [6]. Hence, we here propose the following hypothesis. After HCV infection, the virus core protein enhances the SP1 phosphorylation in hepatocytes, and the phosphorylated SP1 binds to the DNA segment corresponding to the G allele of SNP rs2596538 and then induces *MICA* expression. The membrane-bound MICA (mMICA) serves as a ligand for NKG2D to activate the immune system and results in the elimination of viral-infected cells by NK cells and CD8+ T cells [8,9]. Eventually, HCV-infected individuals with higher MICA level may cause stronger immune response to the infected cells and hence result in a reduced risk for HCC progression. Moreover, the mMICA is then shed by metalloproteinases that are often over-expressed in cancer tissues and convert mMICA to sMICA. This resulted in a significantly increase of sMICA level in the serum of HCV infected patients.

In contrast to HCV-induced HCC, our group had previously identified that higher sMICA level was associated with poor prognosis in HBV-induced HCC patients [33]. Such an opposite effect of *MICA* would be attributable to the difference in downstream pathway between HBV and HCV. HBV virus encodes hepatitis B virus X protein (HBx) that is pathogenic and promotes tumor formation. It had been reported that HBx protein

was associated with an elevated expression of MT1-MMP, MMP2, and MMP3 [34,35]. HBx was also shown to transactivate MMP9 through ERKs and PI-3K-AKT/PKB pathway and suppress TIMP1 and TIMP3 activities [36,37]. The activation of metalloproteinases would induce the shedding of mMICA into sMICA, which promotes the tumor formation through the inhibitory effect of sMICA on NK cells. This can explain why high sMICA expression is a marker of poor prognosis for HBV-induced HCC. On the other hand, HCV infection was not associated with metalloproteinases activation, although the expression of sMICA was shown to be proportional to mMICA level. Therefore individuals with high MICA expression are likely to activate natural killer cells and CD8+ T cells to eliminate virus infected cells.

SP1 was previously identified as a transcriptional regulator of both *MICA* and *MICB* [7,9,38]. A polymorphism in the *MICB* promoter region was found to be associated with *MICB* transcription level [7]. To our knowledge, this is the first report showing that *MICA* transcription is directly influenced by functional variant. Moreover, this functional SNP is significantly associated with HCV-induced HCC. Our findings provide an insight that *MICA* genetic variation is a promising prognostic biomarker for CHC patients.

Supporting Information

Figure S1 Pairwise LD map between marker SNP and 11 candidates SNP. Black color boxes represent regions of high pairwise r^2 value. The LD was determined by direct DNA

sequencing of *MICA* promoter region from 50 randomly selected HCV-HCC patients.
(TIF)

Table S1 Characteristics of samples and methods used in this study.
(DOCX)

Table S2 The sequences of each oligo used in the EMSA and ChIP assay.
(DOCX)

References

- Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K (2009) Epidemiology of hepatocellular carcinoma in Japan. *J Gastroenterol* 44 Suppl 19: 102–107.
- Fassio E (2010) Hepatitis C and hepatocellular carcinoma. *Ann Hepatol* 9 Suppl: 119–122.
- Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, et al. (2011) A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. *Hum Mol Genet* 20: 3884–3892.
- Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, et al. (2009) A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. *Nat Genet* 41: 591–595.
- Zhang H, Zhai Y, Hu Z, Wu C, Qian J, et al. (2010) Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. *Nat Genet* 42: 755–758.
- Kumar V, Kato N, Urabe Y, Takahashi A, Muoyama R, et al. (2011) Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* 43: 455–458.
- Rodriguez-Rodero S, González S, Rodrigo L, Fernández-Morera JL, Martínez-Borra J, et al. (2007) Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1. *Eur J Immunol* 37: 1938–1953.
- Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 285: 727–729.
- Zhang C, Wang Y, Zhou Z, Zhang J, Tian Z (2009) Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. *Cancer Immunol Immunother* 58: 1275–1285.
- Sun D, Wang X, Zhang H, Deng L, Zhang Y (2011) MMP9 mediates MICA shedding in human osteosarcomas. *Cell Biol Int* 35: 569–574.
- Waldhauer I, Goehldorf D, Gieseke F, Weinschenk T, Wittenbrink M, et al. (2008) Tumor-associated MICA is shed by ADAM proteases. *Cancer Res* 68: 6368–6376.
- Jimushi M, Takehara T, Tatsumi T, Kanto T, Groh V, et al. (2003) Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. *Int J Cancer* 104: 354–361.
- Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, et al. (2008) Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. *Cancer Sci* 99: 1643–1649.
- Ota M, Katsuyama Y, Mizuki N, Ando H, Furihata K, et al. (1997) Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uyghur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. *Tissue Antigens* 49: 448–454.
- Nakamura Y (2007) The BioBank Japan Project. *Clin Adv Hematol Oncol* 5: 696–697.
- Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, et al. (2012) A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. *Nat Genet* 44: 430–434, S431–432.
- Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, et al. (2011) Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. *Nat Genet* 43: 797–800.
- Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, et al. (2013) A genome-wide association study of HCV induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at MHC region. *J Hepatol*.
- Scott IJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 316: 1341–1345.
- Consortium GP (2010) A map of human genome variation from population-scale sequencing. *Nature* 467: 1061–1073.
- Venkataraman GM, Suci D, Groh V, Boss JM, Spies T (2007) Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. *J Immunol* 178: 961–969.
- Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. *Nucleic Acids Res* 19: 2499.
- Hata J, Matsuda K, Ninomiya T, Yonemoto K, Matsushita T, et al. (2007) Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction. *Hum Mol Genet* 16: 630–639.
- Barrett JC (2009) Haploview: Visualization and analysis of SNP genotype data. *Cold Spring Harb Protoc* 2009: pdb.ip71.
- Komatsu-Wakui M, Tokunaga K, Ishikawa Y, Leelayuwat C, Kashiwase K, et al. (2001) Wide distribution of the MICA-MICB null haplotype in East Asians. *Tissue Antigens* 57: 1–8.
- Tse KP, Su WH, Yang ML, Cheng HY, Tsang NM, et al. (2011) A gender-specific association of CNV at 6p21.3 with NPC susceptibility. *Hum Mol Genet* 20: 2889–2896.
- Negro F, Alberti A (2011) The global health burden of hepatitis C virus infection. *Liver Int* 31 Suppl 2: 1–3.
- Cabibbo G, Craxi A (2010) Epidemiology, risk factors and surveillance of hepatocellular carcinoma. *Eur Rev Med Pharmacol Sci* 14: 352–355.
- McGlynn KA, London WT (2011) The global epidemiology of hepatocellular carcinoma: present and future. *Clin Liver Dis* 15: 223–243.
- Kadonaga JT, Tjian R (1986) Affinity purification of sequence-specific DNA binding proteins. *Proc Natl Acad Sci U S A* 83: 5889–5893.
- Suske G (1999) The Sp-family of transcription factors. *Gene* 238: 291–300.
- Lee S, Park U, Lee YI (2001) Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites. *Virology* 283: 167–177.
- Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, et al. (2012) Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma. *PLoS One* 7: e44743.
- Ou DP, Tao YM, Tang FQ, Yang LY (2007) The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. *Int J Cancer* 120: 1208–1214.
- Yu FL, Liu HJ, Lee JW, Liao MH, Shih WL (2005) Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. *J Hepatol* 42: 520–527.
- Chung TW, Lee YC, Kim CH (2004) Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. *FASEB J* 18: 1123–1125.
- Kim JR, Kim CH (2004) Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. *Int J Biochem Cell Biol* 36: 2293–2306.
- Andresen L, Jensen H, Pedersen MT, Hansen KA, Skov S (2007) Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. *J Immunol* 179: 8235–8242.

Table S3 Copy number variation between HCV-HCC and control samples.
(DOCX)

Author Contributions

Conceived and designed the experiments: PHYL YN KM. Performed the experiments: PHYL YU VK. Analyzed the data: PHYL YU CT. Contributed reagents/materials/analysis tools: KK NK DM KC MK. Wrote the paper: PHYL KM.

Clinical Cancer Research



Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study

Jiping Wang, Luis G. Carvajal-Carmona, Jen-Hwa Chu, et al.

Clin Cancer Res 2013;19:6430-6437. Published OnlineFirst October 1, 2013.

Updated version	Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-13-0550
------------------------	---

Cited Articles	This article cites by 27 articles, 5 of which you can access for free at: http://clincancerres.aacrjournals.org/content/19/23/6430.full.html#ref-list-1
-----------------------	--

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
----------------------	--

Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
-----------------------------------	--

Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org .
--------------------	---

Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study

Jiping Wang¹, Luis G. Carvajal-Carmona³, Jen-Hwa Chu², Ann G. Zaubler⁴, APC Trial Collaborators, Michikazu Kubo⁵, Koichi Matsuda⁵, Malcolm Dunlop⁶, Richard S. Houlston⁷, Oliver Sieber⁸, Lara Lipton⁸, Peter Gibbs⁸, Nicholas G. Martin⁹, Grant W. Montgomery⁹, Joanne Young¹⁰, Paul N. Baird¹¹, Mark J. Ratain¹², Yusuke Nakamura⁵, Scott T. Weiss², Ian Tomlinson³, and Monica M. Bertagnolli¹

Abstract

Purpose: Identification of single-nucleotide polymorphisms (SNP) associated with development of advanced colorectal adenomas.

Experimental Design: Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence. Genome-wide significance was defined as false discovery rate less than 0.05, unadjusted $P = 7.4 \times 10^{-7}$. Validation phase: results were further evaluated using 4,175 familial colorectal adenoma cases and 5,036 controls from patients of European ancestry [COLOrectal Gene Identification consortium (CORGI), Scotland, Australia, and VQ58].

Results: Our study identified eight SNPs associated with advanced-adenoma risk in the APC trial (rs2837156, rs7278863, rs2837237, rs2837241, rs2837254, rs741864 at 21q22.2, and rs1381392 and rs17651822 at 3p24.1, at $P < 10^{-7}$ level with $OR > 2$). Five variants in strong pairwise linkage disequilibrium (rs7278863, rs2837237, rs741864, rs741864, and rs2837241; $r^2 = 0.8-1$) are in or near the coding region for the tight junction adhesion protein, IGSF5. An additional variant associated with advanced adenomas, rs1535989 [minor allele frequency, 0.11; OR, 2.09; 95% confidence interval (CI), 1.50-2.91], also predicted colorectal cancer development in a validation analysis ($P = 0.019$) using a series of adenoma cases or colorectal cancer (CORGI study) and 3 sets of colorectal cancer cases and controls (Scotland, VQ58, and Australia; $N = 9,211$).

Conclusions: Our results suggest that common polymorphisms contribute to the risk of developing advanced adenomas and might also contribute to the risk of developing colorectal cancer. The variant at rs1535989 may identify patients whose risk for neoplasia warrants increased colonoscopic surveillance. *Clin Cancer Res*; 19(23); 6430-7. ©2013 AACR.

Authors' Affiliations: ¹Department of Surgery, Division of Surgical Oncology, ²Center for Genomic Medicine, Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts; ³Genome Center and Department of Biochemistry and Molecular Medicine, University of California, Davis, California; ⁴Department of Epidemiology and Statistics, Memorial Sloan-Kettering Cancer Center, New York; ⁵RIKEN Center for Genomic Medicine, Tokyo, Japan; ⁶Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Edinburgh; ⁷Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; ⁸Ludwig Colon Cancer Initiative Laboratory, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville; ⁹Genetic and Molecular Epidemiology Laboratories, and ¹⁰Familial Cancer Laboratory, Queensland Institute of Medical Research, Brisbane; ¹¹Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia; and ¹²Department of Medicine, University of Chicago, Chicago, Illinois

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Monica M. Bertagnolli, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Phone: 617-732-8910; Fax: 617-582-6177; E-mail: mbertagnolli@partners.org

doi: 10.1158/1078-0432.CCR-13-0550

©2013 American Association for Cancer Research.

Introduction

Colorectal cancer is a common malignancy, with prevalence in developed nations of 40 to 50 cases per 100,000 individuals (1). Approximately one-third of those diagnosed with colorectal cancer will die of their disease due to diagnosis at a stage not curable by locoregional therapy. Most colorectal cancer cases arise from premalignant adenomas that require years or even decades to progress to invasive disease. Colonoscopy to identify and remove precursor adenomas has been recommended for more than 25 years for patients at high colorectal cancer risk, and recently completed long-term analyses of screened cohorts confirmed the utility of adenoma removal for preventing deaths due to colorectal cancer (2).

Our goal is to understand the biology of colorectal cancer to develop effective prevention and therapy, and also to characterize individual risk in a manner that will identify patients most likely to benefit from colonoscopy to detect